5th Dermatology Drug Development Summit Europe Hotel Palace Berlin, Berlin

Going Beyond Symptomatic Treatment: Uncovering Targetable Pathways, Translational Techniques and Navigating European Healthcare Infrastructure to Advance Novel R and D for Small Molecules, Biologics, mAb’s and beyond!

The huge unmet need for more efficacious and durable therapies in inflammatory-mediated dermatological diseases reinforces the critical importance for the community to unite at the 5th Dermatology Drug Development Summit Europe, to collaboratively address the prevailing barriers facing pipeline progression and patient access in Europe.

With successful clinical readouts from pharma’s targeting of a range of inflammatory mechanisms coming thick and fast, novel drug targets emerging and exciting advances in biomarker-driven drug development, the therapeutic promise for pipelines to achieve superior efficacy and safety for target patient populations is at an all-time high.

This is your only industry-led forum uniting large pharma, biotech, academic and clinician KOLs under the common goal to translate cutting edge R and D towards long term improvements in patient QoL whilst navigating complex European healthcare infrastructure for transforming clinical practice.

Join renowned leaders including Sanofi, Nektar Therapeutics and Moonlake Therapeutics to gain unrivalled insight into pipeline strategies translating Psoriasis and Atopic Dermatitis successes, to first-in-class treatments for itch, Prurigo Nodularis, Acne, Hidradenitis Suppurativa, Chronic Spontaneous Urticaria and more!

Your definitive platform pairing ground-breaking research with expert-led intelligence to evolve your dermatology portfolio, be equipped to deliver novel therapies with superior and long-lasting efficacy this April!